New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42 Published in The Journal of Urology

FLEMINGTON, N.J., March 24, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today announced that data from a preclinical study demonstrate its histone-deacetylase (HDAC) inhibitor AR-42 in combination with cisplatin has a synergistic anti-tumor effect in bladder cancer models. These data were recently published online ahead of print in The Journal of Urology .

AR-42 is a novel oral, broad-spectrum agent therapy currently in early clinical development. As a deacetylase inhibitor of both histone and non-histone proteins, AR-42 has demonstrated greater potency and activity in solid tumors and hematological malignancies when compared in preclinical studies to vorinostat (also known as "SAHA" and marketed as Zolinza® by Merck), the first of four marketed compounds in the class. AR-42 may possess additional histone-independent mechanisms, which may contribute to its superior profile in vitro and in vivo.

The study, led by Arnold I. Chin, MD, PhD, Assistant Professor, Department of Urology at University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center (JCCC), demonstrates the ability of AR-42 to synergize with cisplatin to augment the destruction of bladder cancer cells in vitro and in vivo, and to preferentially target the bladder cancer stem cell population. 1 Specifically, the research shows that the combination of AR-42 and cisplatin synergistically kills bladder cancer cells through apoptosis and influences tumor growth and differentiation in vivo. 1 This synergistic effect may also improve the efficacy and overall response rate of cisplatin, and allow for a lower dosage, resulting in potentially lower toxicities in patients. 1 Furthermore, when tested on specific bladder cancer stem cell populations (marked by surface markers CD44+ and CD49f+), AR-42 showed greater efficacy, with and without cisplatin. 1

Alex Zukiwski, MD, Chief Executive Officer of Arno Therapeutics, commented, "These results are encouraging and, although early, establish preclinical evidence that AR-42 may have potential in conjunction with cisplatin-based chemotherapy in the treatment of bladder cancer. Overall, the findings support further clinical investigation of AR-42 in this indication. We are grateful to lead author Dr. Arnold Chin and his team at UCLA for their research and look forward to additional collaboration as we continue to explore this novel therapy."

Bladder cancer affects more than 54,000 men and 17,000 women in the United States annually, making it the fourth most common cancer among men and ninth most common cancer in women. 2 Bladder cancer treatments have remained unchanged for decades and continue to be mainly composed of cisplatin-based chemotherapy regimens that have limited response rates and efficacy. Research has shown that molecular analysis of bladder cancer reveals a high incidence of mutations in chromatin regulatory genes, suggesting a therapeutic avenue for HDAC inhibitors. 1

About AR-42

AR-42 is a novel oral agent therapy currently in early clinical development. It is a broad-spectrum deacetylase inhibitor of both histone and non-histone proteins, which has demonstrated greater potency and activity in solid tumors and hematological malignancies when compared in preclinical studies to vorinostat (also known as "SAHA" or Zolinza), the first of four marketed compounds in the class. AR-42 may possess additional histone-independent mechanisms, which may contribute to its superior profile in vitro and in vivo. It has been designated an orphan drug by the FDA for the treatment of meningioma and schwannoma of the central nervous system. Meningioma and schwannoma are rare, benign tumors that can present in different locations within the brain and the spinal cord and may cause substantial morbidity.

About Arno Therapeutics

Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer and other life threatening diseases. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit  www.arnothera.com . 

References

1. Li D.R., Zhang H., Peek E., Wang S., Du L., Li G., Chin A.I. Synergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancer. J. Urology. 2015. http://www.jurology.com/article/S0022-5347%28...9/abstract

2. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA. Cancer J. Clin. 2013; 63: 11–30.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the potential of AR-42 as a potential therapy for bladder cancer, the timing, progress and anticipated results of the development of AR-42, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of further preclinical and clinical trials will not support our claims or beliefs concerning the effectiveness of AR-42 or any of our other product candidates, our ability to finance the development of AR-42 and our other product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2013 and its Quarterly Report for the quarter ended September 30, 2014. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

The Ruth Group Lee Roth (investors) (646) 536-7012 Kirsten Thomas (media) (646) 536-7014 Arno Therapeutics Lawrence Kenyon (862) 703-7171

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 98

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 50

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 69

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 78

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 86

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading

Top 5 Most Recently Viewed Articles

Ross Gerber Expresses Optimism for Meta's Phone-Free Future

Updated Category News Views 242

Ross Gerber Praises Meta's Smart Glasses Technology Over the weekend, investor Ross Gerber expressed his admiration for Meta Platforms, Inc. (NASDAQ: META) smart glasses, affirming their potential to transform our relationship with technology. Gerber noted that this innovative eyewear gives him hope for a day when he might no longer rely on his smartphone. Smart Glasses:...

Continue Reading
Organ-on-a-Chip Market Insights and Future Projections

Updated Category News Views 118

Understanding the Organ-on-a-Chip Market Growth As technology evolves, the quest for more accurate and human-relevant drug testing models takes center stage. The Organ-on-a-Chip (OOC) market has emerged as a revolutionary force, previously valued at around USD 117.67 million, and now set to skyrocket to approximately USD 1.64 billion by 2032. This innovative approach is...

Continue Reading
Discovering Blue Light Cystoscopy Benefits in Bladder Cancer

Updated Category News Views 240

New Insights on Blue Light Cystoscopy and Bladder Cancer Photocure ASA, known as the Bladder Cancer Company, has made significant advancements in bladder cancer management with the recent study titled "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO Study." This research published in JU Open Plus provides compelling evidence...

Continue Reading
BioCryst's Bold Move: Astria Therapeutics Acquisition Insights

Updated Category News Views 211

BioCryst Enhances HAE Portfolio with Astria Acquisition BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has made a significant announcement regarding its acquisition of Astria Therapeutics, Inc. (NASDAQ: ATXS). This strategic move will strengthen BioCryst's position in the hereditary angioedema (HAE) market, as they plan to integrate Astria's promising therapies and...

Continue Reading
Milestone Scientific Reaches New Height with Strong Growth

Updated Category News Views 361

Milestone Scientific Achieves 52-Week High Milestone Scientific Inc. (NYSE: MLSS) has reached a significant milestone with its stock trading at $1.28, marking a 52-week high. This impressive achievement highlights the company's robust annual growth and increased investor confidence. As a result, the current market capitalization has reached approximately $97.37 million,...

Continue Reading